Taysha Gene Therapies Files 8-K
Ticker: TSHA · Form: 8-K · Filed: May 14, 2024 · CIK: 1806310
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Taysha Gene Therapies filed an 8-K, standard financial update.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these items.
Why It Matters
This filing indicates Taysha Gene Therapies is providing updates on its financial condition and operations to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant changes in the company's status.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- May 14, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39536 (identifier) — SEC File Number
- 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247 (address) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details are not provided in the header information.
When was this 8-K filed?
The filing was made on May 14, 2024.
What is the company's principal executive office address?
The principal executive offices are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is Taysha Gene Therapies, Inc.'s SEC file number?
The SEC file number for Taysha Gene Therapies, Inc. is 001-39536.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-14 16:18:01
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d833929d8k.htm (8-K) — 24KB
- d833929dex991.htm (EX-99.1) — 70KB
- 0001193125-24-138253.txt ( ) — 229KB
- tsha-20240514.xsd (EX-101.SCH) — 3KB
- tsha-20240514_lab.xml (EX-101.LAB) — 18KB
- tsha-20240514_pre.xml (EX-101.PRE) — 11KB
- d833929d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. Dated: May 14, 2024 By: /s/ Kamran Alam Kamran Alam Chief Financial Officer